Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia

    Journal Title:  Biol Blood Marrow Transplant Primary Author:  ... for 3 consecutive days was 19 (range, 16 to 27) days, to red cell engraftment was 25 (range, 2 to 58) days, and to last ...

    Research Article last updated 01/24/2017 - 10:04am.

  2. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... Lenalidomide could effectively induce red blood cell (RBC) transfusion independence (TI) in patients with ...

    Research Article last updated 11/28/2016 - 9:36am.

  3. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and/or thrombocytopenia who may have required red blood cell or platelet transfusions. The overall response rate was ...

    Research Article last updated 06/23/2016 - 10:17am.

  4. Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes

    ... Hemoglobin thresholds and triggers for blood transfusions have changed over the years moving from a higher to a lower ... clinical trials are looking for a more liberal approach of red cell transfusion and the effect on quality of life as opposed to the ...

    Research Article last updated 06/23/2016 - 9:55am.

  5. Patient Inspires Workplace Giving

    ... experienced what I now know as petechiae – little red dots all over my body caused by bleeding into the skin due to low ... other patients, we first knew something wasn’t right when blood work from a routine physical showed significantly low blood cell counts. ...

    Patient Chronicle last updated 06/28/2016 - 8:12am.

  6. NHLBI profiles a member of the Foundation’s patient community.

    ... One Woman’s Determination Helped Her Defeat a Devastating Blood Disease Article Source:  ... the spongy tissue inside the bones — from making enough red blood cells, which carry oxygen to the different parts of the body; white ...

    Article last updated 06/13/2016 - 1:51pm.

  7. Personalized medicine for MDS

    ... patients into “lower-risk” disease, where improvement in blood counts is the main goal of therapy, and “higher-risk” disease, where ... 2 years.  -Lenalidomide works best in patients with red blood cell transfusion dependent MDS patients with lower-risk disease ...

    Research Review last updated 05/02/2016 - 9:44am.

  8. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... Low endogenous erythropoietin levels and limited red blood cell transfusion history can predict response to ...

    Research Article last updated 08/04/2014 - 8:33am.

  9. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... BACKGROUND: Pure red cell aplasia and moderate aplastic anemia are marrow failure ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with ...

    Research Article last updated 05/26/2015 - 11:49am.